{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:58:14Z","timestamp":1792022294197,"version":"4.4.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"DOI":"10.7759\/cureus.78541","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T12:34:15Z","timestamp":1738758855000},"source":"Crossref","is-referenced-by-count":3,"title":["Safety of Compounded Medications"],"prefix":"10.7759","author":[{"given":"Rohini","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Human Drug Compounding. (2019). Accessed. October 1, 2024: https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/human-drug-compounding."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-020-00814-3","article-title":"Pharmaceutical compounding: a history, regulatory overview, and systematic review of compounding errors","volume":"17","author":"Watson CJ","year":"2021","unstructured":"Watson CJ, Whitledge JD, Siani AM, Burns MM. Pharmaceutical compounding: a history, regulatory overview, and systematic review of compounding errors. J Med Toxicol. 2021, 17:197-217. 10.1007\/s13181-020-00814-3","journal-title":"J Med Toxicol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-013-0005-9","article-title":"Potential risks of pharmacy compounding","volume":"13","author":"Gudeman J","year":"2013","unstructured":"Gudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs R D. 2013, 13:1-8. 10.1007\/s40268-013-0005-9","journal-title":"Drugs R D"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2165\/11640850-000000000-00000","article-title":"Pharmacy compounding primer for physicians: prescriber beware","volume":"72","author":"Sellers S","year":"2012","unstructured":"Sellers S, Utian WH. Pharmacy compounding primer for physicians: prescriber beware. Drugs. 2012, 72:2043-50. 10.2165\/11640850-000000000-00000","journal-title":"Drugs"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ph15091091","article-title":"The role of pharmaceutical compounding in promoting medication adherence","volume":"15","author":"Carvalho M","year":"2022","unstructured":"Carvalho M, Almeida IF. The role of pharmaceutical compounding in promoting medication adherence. Pharmaceuticals (Basel). 2022, 15:1091. 10.3390\/ph15091091","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-24.4.327","article-title":"Standardization of concentrations for extemporaneously compounded oral liquid medications","volume":"24","author":"Smith T","year":"2019","unstructured":"Smith T, Kokotajlo S, Lise J, Passerrello N, Weilnau J, Cash J. Standardization of concentrations for extemporaneously compounded oral liquid medications. J Pediatr Pharmacol Ther. 2019, 24:327-9. 10.5863\/1551-6776-24.4.327","journal-title":"J Pediatr Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1712905","article-title":"Toward better-quality compounded drugs - an update from the FDA","volume":"377","author":"Woodcock J","year":"2017","unstructured":"Woodcock J, Dohm J. Toward better-quality compounded drugs - an update from the FDA. N Engl J Med. 2017, 377:2509-12. 10.1056\/NEJMp1712905","journal-title":"N Engl J Med"},{"key":"ref8","unstructured":"FDA alerts health care professionals of adverse events associated with Guardian\u2019s compounded triamcinolone and moxifloxacin product for intravitreal injection. (2017). Accessed. October 4, 2024: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm569114.htm."},{"key":"ref9","unstructured":"FDA\u2019s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. (2024). Accessed. October 4, 2024: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fdas-concerns-unapproved-glp-1-dr...."},{"key":"ref10","unstructured":"Registered Outsourcing Facilities. (2024). Accessed. October 3, 2024: https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/registered-outsourcing-facilities."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0741-y","article-title":"Compounded medication for patients with rare diseases","volume":"13","author":"Dooms M","year":"2018","unstructured":"Dooms M, Carvalho M. Compounded medication for patients with rare diseases. Orphanet J Rare Dis. 2018, 13:1. 10.1186\/s13023-017-0741-y","journal-title":"Orphanet J Rare Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/339391-safety-of-compounded-medications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T12:34:18Z","timestamp":1738758858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/339391-safety-of-compounded-medications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.78541","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,5]]}}}